53. Sjogren syndrome Clinical trials / Disease details

Clinical trials : 305 / Drugs : 325 - (DrugBank : 104) / Drug target genes : 58 - Drug target pathways : 188

3 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05605665 (ClinicalTrials.gov)	November 5, 2022	29/10/2022	Low-dose Interleukin-2 and Rapamycin on sjögren's Syndrome	Therapeutic Effect of Low Dose IL-2 Combined With Rapamycin in on sjögren's Syndrome	Sjögren's Syndrome	Drug: low-dose interleukin-2;Drug: rapamycin	Peking University People's Hospital	NULL	Recruiting	18 Years	N/A	All	30	Phase 1/Phase 2	China
2	ChiCTR-INR-17011220	2017-04-24	2017-04-23	The Efficacy and Safety of Low Dose IL-2Therapy in Chinese patients with primary Sjogren's syndrome	The Efficacy and Safety of Low Dose IL-2Therapy in Chinese patients with primary Sjogren's syndrome	primary Sj?gren’s syndrome	Ll-2 group:IL-2 treatment; non IL-2 group:conventional treatment;	the Second Hospital of Shanxi Medical University	NULL	Recruiting			Both	Ll-2 group:90; non IL-2 group:90;		China
3	NCT02464319 (ClinicalTrials.gov)	June 1, 2015	30/5/2015	A Phase II Study With Low-dose Recombinant Human IL-2 for the Treatment of Primary Sjögren's Syndrome	Safety and Efficiency Study of Low-dose IL-2 Treatment in Primary Sjögren's Syndrome	Primary Sjögren's Syndrome	Drug: hrIL-2 active;Drug: hrIL-2 placebo	Peking University People's Hospital	Monash University;Beijing ShuangLu Pharmaceutical Co., Ltd.	Completed	18 Years	65 Years	All	60	Phase 2	China